全球伤寒疫苗市场 – 2029 年行业趋势及预测

市场分析和规模                              

根据《柳叶刀：传染病》杂志发表的一项研究，伤寒感染了全球 2160 万人，每年导致约 20 万人死亡。此外，拉丁美洲和其他发展中经济体的经济不稳定导致卫生条件差，无法获得干净的水和食物，使人们面临感染伤寒的风险。伤寒沙门氏菌会引起伤寒，导致高烧、头痛、食欲不振、便秘和恶心等症状。伤寒主要传播在卫生条件差和水污染的地区。伤寒疫苗是一种生物制剂，可为人类提供免疫力和保护，防止其感染伤寒。

Data Bridge Market Research 分析称，2021 年伤寒疫苗市场价值为 3.2148 亿美元，预计到 2029 年将达到 7.1977 亿美元，在 2022 年至 2029 年的预测期内复合年增长率为 10.6%。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

报告范围和市场细分

Market Definition

Typhoid fever, commonly known as Salmonella typhi or Salmonella enterica serotype Typhi, is a bacterial infection caused by Salmonella typhi. Typhoid fever is most commonly caused by consuming contaminated food or water. Typhoid immunizations help to prevent and protect against typhoid fever. The World Health Organization (WHO) has advised using three types of typhoid vaccines: live attenuated vaccine, capsular polysaccharide vaccines, and conjugate vaccines.

Typhoid Vaccine Market Dynamics

Drivers

• Rise in the prevalence of typhoid

The surging prevalence of typhoid in various emerging economies is a major factor driving the typhoid vaccine market's growth rate during the forecast period of 2022 to 2029. According to estimates from the International Health Metrics and Evaluation (IHME), over 12 million cases of typhoid fever were reported worldwide in 2016, resulting in around 130,000 deaths. The risk of typhoid is increased among people who do not have access to clean water and sanitation. Poor communities and vulnerable people, such as children, are particularly vulnerable.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of typhoid vaccine market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the typhoid vaccine market. Additionally, the sedentary lifestyle of people and surging geriatric population will result in the expansion of the typhoid vaccine market. Along with this, the presence of immunization campaigns across the globe and favourable reimbursement policies will enhance the market's growth rate.

Opportunities

• Rising number of government initiatives for the development of innovative products

The rising number of government initiatives to develop innovative products is expected to provide beneficial market opportunities. World Health Organization (WHO), Gavi, Bill and Melinda Gates Foundation, and others are all working hard to raise awareness about typhoid and drive immunization efforts against the disease. In December 2017, the World Health Organization (WHO) pre-qualified Typbar TCV, a typhoid conjugate vaccine (TCV) manufactured by Bharat Biotech. The vaccine can now be purchased and delivered to nations funded by UNICEF, the Pan-American Health Organization (PAHO), and the GAVI (Vaccine Alliance). Various companies' regular initiatives are projected to assist market expansion during the forecast period.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the typhoid vaccine market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with vaccine and its development will obstruct the market's growth rate. Developing economies' lack of healthcare infrastructure and the dearth of skilled professionals will challenge the typhoid vaccine market. Additionally, side effects of vaccine such as pain and mild fever will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This typhoid vaccine market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the typhoid vaccine market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

The World Health Organization estimates that 11-20 million cases of typhoid fever occur globally each year, resulting in 128 000–161 000 fatalities.

Typhoid vaccine market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Typhoid Vaccine Market

COVID-19 疫情已成为全球最严重的威胁。这一问题令人担忧，尤其是在世界各地的发展中国家，因为全球贸易中断将导致进口减少，从而加剧医疗用品和其他物品的短缺，导致价格大幅上涨。世界卫生组织和联合国儿童基金会对全球接受救命免疫接种的儿童数量下降表示担忧。这是由于 COVID-19 疫情扰乱了疫苗接种计划的实施和接受。2019 年，联合国儿童基金会为 100 多个国家购买了约 24.3 亿剂疫苗，覆盖了全球约 45% 的五岁以下儿童。然而，公司经常使用产品发布和扩张策略来扩大其全球影响力并满足不断增长的需求。市场参与者经常使用这些策略来增强其产品组合。

近期发展

• 2022 年 4 月，尼泊尔政府宣布在全国常规免疫计划中启动一项名为伤寒结合疫苗 (TCV) 的新疫苗接种活动。该计划与 Gavi、疫苗联盟、联合国儿童基金会、世卫组织和其他合作伙伴合作。该计划的目标是让大约 750 万名儿童获得 95% 的伤寒结合疫苗 (TCV) 接种率，同时确定“零剂量”儿童和错过其他常规免疫接种的儿童。

全球伤寒疫苗市场范围

伤寒疫苗市场根据类型、给药途径、最终用户和分销渠道进行细分。这些细分市场之间的增长情况将帮助您分析行业中增长缓慢的细分市场，并为用户提供有价值的市场概览和市场洞察，帮助他们做出战略决策，确定核心市场应用。

类型

• 减毒活疫苗
• 单价伤寒疫苗
• 荚膜多糖疫苗
• 结合疫苗
• 其他的

给药途径

• 口服
• 肠外

最终用户

• 医院
• 专科诊所
• 家庭护理
• 其他的

分销渠道

• 医院药房
• 零售药店
• 网上药店
• 其他的

伤寒疫苗市场区域分析/见解

对伤寒疫苗市场进行了分析，并按国家、类型、给药途径、最终用户和分销渠道提供了市场规模见解和趋势。

伤寒疫苗市场报告涵盖的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区

北美在市场份额和市场收入方面占据伤寒疫苗市场的主导地位，并将在预测期内继续保持主导地位。这是由于主要关键参与者的存在以及医疗保健支出的增加将进一步推动该地区市场的增长速度。此外，患者意识的提高和对疫苗的高需求将进一步推动该地区市场的增长速度。

由于伤寒病发病率激增和该地区有利的监管指导方针，预计亚太地区将在 2022-2029 年预测期内实现增长。此外，医疗保健基础设施的发展和政府免疫计划举措的不断增加将进一步推动该地区市场的增长率。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和伤寒疫苗市场份额分析

伤寒疫苗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对伤寒疫苗市场的关注有关。

伤寒疫苗市场的一些主要参与者包括：

• 辉瑞公司（美国）
• 葛兰素史克公司 (英国)
• 诺华公司（瑞士）
• Mylan NV（美国）
• Teva Pharmaceutical Industries Ltd.（以色列）
• 赛诺菲（法国）
• 阿斯利康（英国）
• 强生私人有限公司（美国）
• 默克公司（美国）
• F. Hoffmann-La Roche Ltd.（瑞士）
• 生物梅里埃公司（法国）
• 安进公司 (美国)
• 武田药品工业株式会社 (日本)
• 太阳制药工业有限公司 (印度)
• 鲁冰花（印度）
• Mallinckrodt（美国）
• 新兴市场（美国）
• Bio Farma（印度尼西亚）
• Bharat Biotech（印度）
• BIO-MED（印度）

SKU-53233